You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


Tallac announces first patient treated with TAC-001

Tallac Therapeutics has announced that the first patient has been treated with TAC-001 in a phase 1/2 clinical trial for patients with advanced or metastatic solid tumours.